NBE-Therapeutics engages in the development of “next-generation”, immune-stimulatory antibody drug conjugates (iADCs) with the objective to develop best-in-class ADC product candidates until clinical proof-of-concept in patients.

NBE Therapeutics joined the Boehringer-Ingelheim group of companies.

Products, services, technology

NBE-002, an anti-ROR1 iADC

Cooperation possibilities

Technology and early ADC development candidate partnering for joint development into the clinic.

  • Hochbergerstrasse 60C - Technology Park Basel, 4057 Basel, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in